Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
Recruiting · NCT06607757 · Registry updated 2025-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer | CCCA Assessed by Ki67 Drop Below <2.7% From Baseline | Recruiting | Phase 2 | 2025-04-02 | NCT06607757 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| GBG Forschungs GmbH | 12 |
25 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.